Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

Publication date: Available online 27 January 2021Source: The Lancet Respiratory MedicineAuthor(s): Cornedine J de Gooijer, Vincent van der Noort, Jos A Stigt, Paul Baas, Bonne Biesma, Robin Cornelissen, Nico van Walree, Robbert C van Heemst, Magdolen Youssef-El Soud, Harry J M Groen, Agnes J Staal-van den Brekel, Wieneke A Buikhuisen, Gerben P Bootsma, Floris Dammeijer, Harm van Tinteren, Ferry Lalezari, Joachim G Aerts, Jacobus A Burgers, NVALT19 study group
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research